Biomarkers indicative of prostate cancer and treatment thereof
Described herein are materials and methods for the treatment of prostate cancer.
1. A method of decreasing proliferation of prostate cancer cells comprising contacting the cells with doxorubicin (DOX) and N9-isopropylolomoucine (N-9) in an amount effective to decrease proliferation of the cancer cells, wherein the prostate cancer is castrate-resistant prostate cancer (CRPC).
2. The method of claim 1 , wherein the CRPC cells are selected from the group consisting of 22Rv1 cells and C4-2B cells.
3. The method of claim 1 , wherein the amount of DOX in the combination is less than 2 mg/mL.
4. The method of claim 1 , wherein the amount of N-9 in the combination is less than 2 mg/mL.
5. A method of treating prostate cancer in a subject in need thereof comprising administering to the subject doxorubicin (DOX) and N9-isopropylolomoucine (N-9) a mitotic cyclin dependent kinase inhibitor in amounts effective to treat prostate cancer in the subject, wherein the prostate cancer is castrate-resistant prostate cancer (CRPC).
6. The method of claim 5 , wherein the subject is resistant to treatment with enzalutamide.
7. The method of claim 5 , wherein the DOX and N-9 are administered to the subject in separate compositions.
8. The method of claim 5 , wherein the DOX and N-9 are administered in the same composition.
9. The method of claim 7 , wherein DOX is administered within 24 hours of N-9.
10. The method of claim 5 , wherein the amount of the DOX in the combination is less than 2 mg/mL.
11. The method of claim 5 , wherein the amount of N-9 in the combination is less than 2 mg/mL.
12. The method of claim 5 , further comprising administering a further therapeutic agent selected from the group consisting of an androgen receptor antagonist, an inhibitor of androgen synthesis, a gonadotropin-releasing hormone (GnRH) agonist and a GnRH antagonist to the subject.
13. A method of treating prostate cancer in a subject in need thereof comprising
(a) identifying elevated levels of kinesin family-member 20A (KIF20A), kinesin family-member 23 (KIF23), topoisomerase DNA II alpha (TOP2A), cyclin B1 (CCNB1) cyclin B2 (CCNB2), mitotic checkpoint serine/threonine kinase (BUB1) and mitotic checkpoint serine/threonine kinase B (BUB1b) in a tumor sample from the subject relative to a reference standard; and
(b) administering doxorubicin (DOX) and a mitotic cyclin dependent kinase inhibitor in amounts effective to treat prostate cancer in the subject.
14. The method of claim 13 , wherein the prostate cancer is castrate-resistant prostate cancer (CRPC).